SCHEMBL12508682

SCHEMBL12508682

O=C(CN1CCN(c2ccc(Cl)cc2)CC1)Nc1ccc2[nH]c(=O)oc2c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.62
LMNA P02545 3/20 0.62
TSHR P16473 3/20 0.62
CYP1A2 P05177 2/20 0.62
CYP3A4 P08684 2/20 0.62
CYP2D6 P10635 2/20 0.62
CYP2C9 P11712 2/20 0.62
CYP2C19 P33261 2/20 0.62
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
ENPP2 Q13822 1/20 0.61
HTT P42858 2/20 0.59
FPR2 P25090 1/20 0.59
TP53 P04637 1/20 0.57
ALDH1A1 P00352 2/20 0.57
KCNH2 Q12809 1/20 0.56
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
CA7 P43166 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12508680 0.88 ALOX15 (0.61) MAPTLMNATSHRCYP1A2CYP3A4
SCHEMBL12508282 0.88 ENPP2 (0.57) MAPTLMNATSHRCYP1A2CYP3A4
SCHEMBL12232767 0.88 ENPP2 (0.57) MAPTLMNATSHRCYP1A2CYP3A4
SCHEMBL12232964 0.87 ENPP2 (0.59) MAPTLMNATSHRCYP1A2CYP3A4
SCHEMBL12508777 0.87 ENPP2 (0.59) MAPTLMNAENPP2TP53ALDH1A1
SCHEMBL12232257 0.87 GRIN2D (0.49) MAPTLMNATSHRCYP1A2CYP3A4
SCHEMBL12232657 0.85 ENPP2 (0.55) MAPTLMNATSHRCYP1A2CYP3A4
SCHEMBL12508483 0.85 GRIN2D (0.51)
SCHEMBL12232785 0.85 ENPP2 (0.58) MAPTTSHRMEN1KMT2AENPP2
SCHEMBL12232661 0.85 ENPP2 (0.60) MAPTLMNAKMT2AENPP2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110172415-A1 NITROGEN-CONTAINING HETEROCYCLE DERIVATIVES SUBSTITUTED WITH CYCLIC GROUP SHIONOGI & CO., LTD. (JP) 2011-07-14 US disclosed
US-7935706-B2 Nitrogen-containing heterocycle derivatives substituted with cyclic group SHIONOGI & CO., LTD. (JP) 2011-05-03 US disclosed
US-7935706-B2 Nitrogen-containing heterocycle derivatives substituted with cyclic group SHIONOGI & CO., LTD. (JP) 2011-05-03 US disclosed
US-20090062261-A1 NITROGEN-CONTAINING HETEROCYCLE DERIVATIVES SUBSTITUTED WITH CYCLIC GROUP SHIONOGI & CO., LTD. (JP) 2009-03-05 US disclosed
US-20090062261-A1 NITROGEN-CONTAINING HETEROCYCLE DERIVATIVES SUBSTITUTED WITH CYCLIC GROUP SHIONOGI & CO., LTD. (JP) 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172415-A1 NITROGEN-CONTAINING HETEROCYCLE DERIVATIVES SUBSTITUTED WITH CYCLIC GROUP NR4A1, NR0B2, NR0B1 MAPT 3860/4885LMNA 3424/4885TSHR 152/4885
US-20090062261-A1 NITROGEN-CONTAINING HETEROCYCLE DERIVATIVES SUBSTITUTED WITH CYCLIC GROUP NR4A1, NR0B2, NR0B1 MAPT 3860/4885LMNA 3424/4885TSHR 152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.